Mode
Text Size
Log in / Sign up
N/A N=127 Treatment

Deep Brain Stimulation (DBS) for the Suppression of Tremor

Tremor · Action Tremor · Essential Tremor · Tremor, Limb

Enrolled (actual)
127
Serious AEs
22.1%
Results posted
Feb 2021
Primary outcome: Primary: Primary Efficacy Endpoint: Difference in the Postural Tremor Score of the Target Limb Between Stimulation On and Stimulation Off, As Assessed by the Blind Reviewer — 2.09; 0.84; -1.25 units on a scale

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
ANS Totally Implantable Deep Brain Stimulation System (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Abbott Medical Devices
Primary completion
Apr 2014

Outcome Measures

OutcomeResultp-value
PRIMARY
Primary Efficacy Endpoint: Difference in the Postural Tremor Score of the Target Limb Between Stimulation On and Stimulation Off, As Assessed by the Blind Reviewer
2.09; 0.84; -1.25
PRIMARY
Primary Safety Endpoint: Percentage of Participants With Device-related or Procedure Related Adverse Events
31.5
SECONDARY
Clinical Rating Scale for Tremor (CRST) Evaluation- Mean Target Limb Severity Score, As Assessed by the Site Physician
2.55; 0.62; -1.94
SECONDARY
Clinical Rating Scale for Tremor (CRST) Evaluation- Mean Target Limb Severity Score, As Assessed by the Site Physician
2.55; 0.62; -1.94
SECONDARY
Clinical Rating Scale for Tremor (CRST) Evaluation- Mean Target Limb Severity Score, As Assessed by the Site Physician
2.55; 0.62; -1.94
SECONDARY
Clinical Rating Scale for Tremor (CRST) Evaluation- Mean Target Limb Severity Score, As Assessed by the Site Physician
2.55; 0.62; -1.94
SECONDARY
Clinical Rating Scale for Tremor (CRST) Evaluation- Target Limb Responder Analysis, As Assessed by the Site Physician
72; 97
SECONDARY
Clinical Rating Scale for Tremor (CRST) Evaluation- Target Limb Responder Analysis, As Assessed by the Site Physician
72; 97
SECONDARY
Clinical Rating Scale for Tremor (CRST) Evaluation- Target Limb Responder Analysis, As Assessed by the Site Physician
72; 97
SECONDARY
Clinical Rating Scale for Tremor (CRST) Evaluation- Mean Handwriting for Target Side Severity Score, As Assessed by the Site Physician
2.32; 0.90; -1.42
SECONDARY
Clinical Rating Scale for Tremor (CRST) Evaluation- Mean Handwriting for Target Side Severity Score, As Assessed by the Site Physician
2.32; 0.90; -1.42
SECONDARY
Clinical Rating Scale for Tremor (CRST) Evaluation- Mean Handwriting for Target Side Severity Score, As Assessed by the Site Physician
2.32; 0.90; -1.42
SECONDARY
Clinical Rating Scale for Tremor (CRST) Evaluation- Mean Handwriting for Target Side Severity Score, As Assessed by the Site Physician
2.32; 0.90; -1.42
SECONDARY
Clinical Rating Scale for Tremor (CRST) Evaluation- Mean Handwriting for Target Side Severity Score, As Assessed by the Blind Reviewer
1.69; 0.62; -1.07
SECONDARY
Clinical Rating Scale for Tremor (CRST) Evaluation- Mean Pouring From Target Side Severity Scores, As Assessed by the Site Physician
2.08; 0.57; -1.52
SECONDARY
Clinical Rating Scale for Tremor (CRST) Evaluation-Mean Pouring From Target Side Severity Scores, As Assessed by the Site Physician
2.16; 0.62; -1.54
SECONDARY
Clinical Rating Scale for Tremor (CRST) Evaluation- Mean Pouring From Target Side Severity Scores, As Assessed by the Site Physician
2.08; 0.57; -1.52
SECONDARY
Clinical Rating Scale for Tremor (CRST) Evaluation-Mean Pouring From Target Side Severity Scores, As Assessed by the Site Physician
2.16; 0.62; -1.54
SECONDARY
Clinical Rating Scale for Tremor (CRST) Evaluation- Pouring Ability From Target Side Severity Scores, As Assessed by the Blind Reviewer
1.56; 0.70; -0.86
SECONDARY
Clinical Rating Scale for Tremor (CRST) Evaluation- Mean Total Motor Score, As Assessed by the Site Physician
14.6; 7.2; -7.4
SECONDARY
Clinical Rating Scale for Tremor (CRST) Evaluation- Mean Total Motor Score, As Assessed by the Site Physician
14.6; 7.2; -7.4
SECONDARY
Clinical Rating Scale for Tremor (CRST) Evaluation- Mean Total Motor Score, As Assessed by the Site Physician
14.6; 7.2; -7.4
SECONDARY
Clinical Rating Scale for Tremor (CRST) Evaluation- Mean Total Motor Score, As Assessed by the Site Physician
14.6; 7.2; -7.4
SECONDARY
Clinical Rating Scale for Tremor (CRST) Evaluation- Activity of Daily Living Score, As Assessed by the Site Physician
14.7; 4.6; -10.0
SECONDARY
Clinical Rating Scale for Tremor (CRST) Evaluation- Activity of Daily Living Score, As Assessed by the Site Physician
14.7; 4.6; -10.0
SECONDARY
Clinical Rating Scale for Tremor (CRST) Evaluation- Activity of Daily Living Score, As Assessed by the Site Physician
14.7; 4.6; -10.0
SECONDARY
Clinical Rating Scale for Tremor (CRST) Evaluation- Activity of Daily Living Score, As Assessed by the Site Physician
14.7; 4.6; -10.0
SECONDARY
Clinical Rating Scale for Tremor (CRST) Evaluation-Bilateral Stimulation, As Assessed by the Site Physician
2.67; 0.95; -1.72
SECONDARY
Clinical Rating Scale for Tremor (CRST) Evaluation-Bilateral Stimulation, As Assessed by the Site Physician
2.67; 0.95; -1.72
SECONDARY
Clinical Rating Scale for Tremor (CRST) Evaluation-Non-Target Limb Severity Scores, As Assessed by the Site Physician
2.73; 1.11; -1.62
SECONDARY
Clinical Rating Scale for Tremor (CRST) Evaluation-Non-Target Limb Severity Scores, As Assessed by the Site Physician
2.73; 1.11; -1.62
SECONDARY
Quality of Life in Essential Tremor (QUEST): Overall Summary Index
49.1
SECONDARY
Change From Baseline for Quality of Life in Essential Tremor (QUEST): Overall Summary Index
30.9; -18.0
SECONDARY
Change From Baseline for Quality of Life in Essential Tremor (QUEST): Overall Summary Index
30.9; -18.0
SECONDARY
Change From Baseline for Quality of Life in Essential Tremor (QUEST): Overall Summary Index
30.9; -18.0
SECONDARY
SF36 Components and Individual Domains
45.6; 52.21
SECONDARY
SF36 Components and Individual Domains
45.6; 52.21
SECONDARY
SF36 Components and Individual Domains
45.6; 52.21
SECONDARY
SF36 Components and Individual Domains
45.6; 52.21
SECONDARY
Global Assessment Scores by Examiner
36; 55; 14; 4; 1
SECONDARY
Global Assessment Scores by Examiner
36; 55; 14; 4; 1
SECONDARY
Global Assessment Scores by Examiner
36; 55; 14; 4; 1
SECONDARY
Global Assessment Scores by Examiner
36; 55; 14; 4; 1
SECONDARY
Global Assessment by Caregiver
25; 28; 11; 4; 2
SECONDARY
Global Assessment by Caregiver
25; 28; 11; 4; 2
SECONDARY
Global Assessment by Caregiver
25; 28; 11; 4; 2
SECONDARY
Global Assessment by Caregiver
25; 28; 11; 4; 2
SECONDARY
Global Assessment by Patient
38; 45; 20; 6; 1
SECONDARY
Global Assessment by Patient
38; 45; 20; 6; 1
SECONDARY
Global Assessment by Patient
38; 45; 20; 6; 1
SECONDARY
Global Assessment by Patient
38; 45; 20; 6; 1
SECONDARY
Subjective Assessment by Patient Since Activation of System
17; 13; 16; 45; 14; 3
SECONDARY
Subjective Assessment by Patient Since Activation of System
17; 13; 16; 45; 14; 3
SECONDARY
Subjective Assessment by Patient Since Activation of System
17; 13; 16; 45; 14; 3
SECONDARY
Number of Participants With Satisfaction With the DBS System's Functioning and Ability to Control Symptoms
76; 22; 2; 7; 3
SECONDARY
Number of Participants With Satisfaction With the DBS System's Functioning and Ability to Control Symptoms
76; 22; 2; 7; 3
SECONDARY
Number of Participants With Satisfaction With the DBS System's Functioning and Ability to Control Symptoms
76; 22; 2; 7; 3
SECONDARY
Number of Participants Who Would Choose to Receive the DBS System Again
98
SECONDARY
Number of Participants Who Would Choose to Receive the DBS System Again
98
SECONDARY
Number of Participants Who Would Choose to Receive the DBS System Again
98
SECONDARY
Number of Participants Who Would Recommend the DBS System
98
SECONDARY
Number of Participants Who Would Recommend the DBS System
98
SECONDARY
Number of Participants Who Would Recommend the DBS System
98
SECONDARY
Beck Depression Inventory II (BDI - II) Score for Depression Symptoms
8.8
SECONDARY
Change From Baseline in Beck Depression Inventory II (BDI - II) Score for Depression Symptoms
6.8; -2.0
SECONDARY
Mini Mental State Exam (MMSE) for Examination of Mental Status
29.2
SECONDARY
Change From Baseline in Mini Mental State Exam (MMSE) For Examination of Mental Status
29.1; -0.1

Summary

The purpose of the proposed study is to demonstrate the safety and efficacy of the ANS Totally Implantable Deep Brain Stimulation System in the VIM nucleus of the thalamus implanted for the treatment of tremor due to essential tremor. This study will be included in the Pre-Market Approval Application to support the safety of this device in use.

Eligibility Criteria

Inclusion criteria

  • Patient or authorized representative has signed an informed consent.
  • Patient is over 18 years of age.
  • Patient is diagnosed with essential tremor for at least 3 years.
  • Patient has a disabling medical-refractory upper extremity tremor with no evidence of supraspinal central nervous system disease or injury (tremor not adequately controlled by medications for at least three (3) months before implant).
  • Patient has a postural or kinetic tremor severity score of at least 3 out of 4 in the extremity intended for treatment on the Fahn-Tolosa-Marin Clinical Rating Scale for Tremor.
  • Patient will maintain a constant dose of anti-tremor medication indicated as best medical management for one (1) month prior to enrollment in study.
  • Patient is available for appropriate follow-up times for the length of the study.

Exclusion criteria

  • Patient is not surgical candidate;
  • Patient has other clinically or medically significant disease;
  • Patient has any neurological injury or disease other than essential tremor;
  • Patient has any condition requiring repeated MRI scans;
  • Patient has any condition requiring diathermy;
  • Patients on anticoagulant medications;
  • Patient has untreated clinically significant depression;
  • Patient has had an electrical or electromagnetic implant (cochlear prosthesis, pacemaker etc);
  • Patient has had a prior thalamotomy or surgical ablation procedure in either side of the brain;
  • Patient has dementia interfering with their ability to co-operate or comply with study requirements or comprehend the informed consent (mini-mental exam score <24);
  • Patient abuses drugs or alcohol;
  • Patient has had botulinum toxin injections in the six (6) months prior to enrollment;
  • Patient has a history of cranial surgery;
  • Patient has a history of seizures;
  • Patient has any metallic implants that may interfere with the functioning of the device (e.g. aneurysm clips);
  • Patient has a history of stimulation intolerance in any area of the body;
  • Patient is a female of child bearing potential with a positive urine pregnancy test or not using adequate contraception.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02087046). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search